Title |
Medical bioremediation of age-related diseases
|
---|---|
Published in |
Microbial Cell Factories, April 2009
|
DOI | 10.1186/1475-2859-8-21 |
Pubmed ID | |
Authors |
Jacques M Mathieu, John Schloendorn, Bruce E Rittmann, Pedro JJ Alvarez |
Abstract |
Catabolic insufficiency in humans leads to the gradual accumulation of a number of pathogenic compounds associated with age-related diseases, including atherosclerosis, Alzheimer's disease, and macular degeneration. Removal of these compounds is a widely researched therapeutic option, but the use of antibodies and endogenous human enzymes has failed to produce effective treatments, and may pose risks to cellular homeostasis. Another alternative is "medical bioremediation," the use of microbial enzymes to augment missing catabolic functions. The microbial genetic diversity in most natural environments provides a resource that can be mined for enzymes capable of degrading just about any energy-rich organic compound. This review discusses targets for biodegradation, the identification of candidate microbial enzymes, and enzyme-delivery methods. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 4% |
Japan | 1 | 2% |
Uruguay | 1 | 2% |
Brazil | 1 | 2% |
Unknown | 45 | 90% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 9 | 18% |
Student > Ph. D. Student | 8 | 16% |
Researcher | 7 | 14% |
Student > Bachelor | 5 | 10% |
Professor | 4 | 8% |
Other | 9 | 18% |
Unknown | 8 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 24 | 48% |
Medicine and Dentistry | 8 | 16% |
Biochemistry, Genetics and Molecular Biology | 4 | 8% |
Engineering | 2 | 4% |
Chemistry | 2 | 4% |
Other | 3 | 6% |
Unknown | 7 | 14% |